Gutierrez Nicholas M, Newhouse Jeffrey H
From the Columbia University Medical Center, New York, NY.
J Comput Assist Tomogr. 2017 Nov/Dec;41(6):976-982. doi: 10.1097/RCT.0000000000000624.
Contrast nephropathy occurs more frequently after cardiac angiography, which usually includes left ventriculography via direct left ventricular injection, than after contrast-enhanced computed tomography (CT), despite the usually higher intravenous contrast dose used for CT. To determine whether maximum renal arterial contrast concentration is higher after left ventriculography, we assessed this parameter for both procedures.
Contrast concentration in abdominal aortic blood during contrast-enhanced CT was measured by performing CT densitometry of aortic blood before contrast, and in the arterial phase, in 100 adults undergoing abdominal CT. Densities were converted to contrast concentrations by scanning water phantoms containing 20 graded concentrations of contrast and comparing their densities to patient data. Because it was impossible to perform CT densitometry during cardiac angiography, aortic contrast concentrations were calculated from standard contrast doses and injection rates with the range of clinically encountered cardiac output rates, assuming ultimate steady state for blood/contrast mixing and normal data distribution.
Maximum aortic (and hence renal arterial) concentrations were significantly higher (range, 6.68%-15.90%) after ventriculography than after CT (1.22%-5.80%). Because ventricular injection times are much shorter than published initial-appearance-to-maximum-concentration times after intravenous administration, the rate of change of contrast concentration is also higher after ventriculography than after CT.
Higher maximum renal arterial contrast concentration may be responsible for the greater risk of nephropathy after cardiac angiography than after doses for CT. The faster rate of change of renal arterial contrast concentration after ventriculography may also increase the likelihood of renal toxicity.
CLINICAL RELEVANCE/APPLICATION: Maximum renal arterial contrast concentration, and/or the rapidity of change of this parameter, may be partly responsible for the risk of nephropathy. Controlling these factors might permit reduction of nephropathy risk; they also suggest avenues of research into the pathophysiology of contrast nephropathy.
与对比增强计算机断层扫描(CT)相比,尽管CT通常使用更高的静脉造影剂剂量,但对比剂肾病在心脏血管造影术后更频繁发生,心脏血管造影通常包括通过直接左心室注射进行左心室造影。为了确定左心室造影术后肾动脉最大对比剂浓度是否更高,我们评估了这两种检查的该参数。
在100例接受腹部CT检查的成年人中,通过在造影剂注射前及动脉期对主动脉血进行CT密度测定,测量对比增强CT期间腹主动脉血中的造影剂浓度。通过扫描含有20种不同浓度造影剂的水模体,并将其密度与患者数据进行比较,将密度转换为造影剂浓度。由于在心脏血管造影期间无法进行CT密度测定,假设血液/造影剂混合达到最终稳态且数据分布正常,根据标准造影剂剂量和注射速率以及临床常见的心输出量范围计算主动脉造影剂浓度。
左心室造影术后主动脉(以及因此肾动脉)的最大浓度显著高于CT术后(范围为6.68% - 15.90%比1.22% - 5.80%)。由于心室注射时间远短于静脉给药后公布的首次出现至最大浓度时间,左心室造影术后造影剂浓度的变化率也高于CT术后。
肾动脉最大对比剂浓度较高可能是心脏血管造影术后对比剂肾病风险高于CT术后的原因。左心室造影术后肾动脉造影剂浓度变化更快也可能增加肾毒性的可能性。
临床相关性/应用:肾动脉最大对比剂浓度和/或该参数变化的快速性可能部分导致对比剂肾病风险。控制这些因素可能会降低对比剂肾病风险;它们还为对比剂肾病病理生理学的研究提供了途径。